Evidence map›Paper›PMID 20622986›Full record

ArticlePhytochemistry reviews : proceedings of the Phytochemical Society of Europe2009

Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors.

Dale G Nagle, Yu-Dong Zhou

Open access · greenAbstract read
In one paragraph

Article in Phytochemistry reviews : proceedings of the Phytochemical Society of Europe, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. The power of heteronemin in cancers.Journal of biomedical science · 2022
    Review
  3. Review
  4. Article
  5. Bromoperoxidase ProducingMarine drugs · 2019
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. A molecular method for the delivery of small molecules and proteins across the cell wall of algae using molecular transporters.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dale G NagleDepartment of Pharmacognosy and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA.
Yu-Dong Zhou
University of Mississippi · US

Funding

ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIAR01CA098787 · NCI · UNIVERSITY OF MISSISSIPPI · PI NAGLE, DALE G · 2004 to 2013
$2.4M
ANTICANCER DRUG DISCOVERY THAT TARGETS TUMOR HYPOXIAR56CA098787 · NCI · UNIVERSITY OF MISSISSIPPI · PI NAGLE, DALE G · 2008 to 2008
$264k
NCI NIH HHS R01 CA098787NCI NIH HHS R56 CA098787
6 · The paper itself

Abstract

Marine natural products have become a major source of new chemical entities in the discovery of potential anticancer agents that potently suppress various antitumor molecular targets. As a consequence of insufficient vascularization, hypoxic regions form within rapidly growing solid tumor masses. Specific alterations of gene expression in these hypoxic tumor cells help facilitate the survival and metastatic spread of solid tumors. The transcriptional response to cellular hypoxia is primarily mediated by the transcription factor hypoxia-inducible factor-1 (HIF-1) that regulates the expression of more than 100 genes involved in cellular adaptation and survival under hypoxic stress. Clinical studies in cancer patients indicate that HIF-1 activation is directly correlated with advanced disease stages and treatment resistance. HIF-1 has emerged as an important tumor-selective molecular target for anticancer drug discovery. As a result, natural product-based inhibitors of HIF-1 activation have been identified from plants and microorganisms. Recently, structurally unique natural products from marine sponges, crinoids, and algae have been identified as HIF-1 activation inhibitors. The US National Cancer Institute's Open Repository of marine invertebrate and algae extracts has proven to be a valuable source of natural product HIF-1 inhibitors. Among the active compounds identified, certain marine natural products have also been shown to suppress the hypoxic induction of HIF-1 target genes such as vascular endothelial growth factor (VEGF). Some of these marine HIF-1 inhibitors act by interfering with the generation of mitochondrial signaling molecules in hypoxic cells. However, the precise mechanisms of action for many newly identified marine natural product HIF-1 inhibitors remain unresolved.

Identifiers

PMID20622986
PMCPMC2901131
OpenAlexW2020672699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.